Northwestern Events Calendar

Hide past events

Feb
8
2019

Cardiovascular Epidemiology Seminar Series

SHOW DETAILS

When: Friday, February 8, 2019
11:00 AM - 12:00 PM CT

Where: 680 N. Lake Shore Drive, Stamler Conference room, Ste 1400, Chicago, IL 60611 map it

Contact: Putri Kusumo   (312) 908-1718

Group: Department of Preventive Medicine

Category: Academic

Description:

Emily Vargas, MS

PhD Candidate in Psychology
Personality and Social Contexts
Department of Psychology
The University of Michigan

 


Presentation Title:
Psychological Health and Context: Implications
for Health Outcomes and Disparities



Objectives:
My objectives are (a) to explore the significance of psychosocial factors, such as locus of control, and John Henryism, in shaping health outcomes and health behaviors (b) and to highlight the role of culture and context and respect in shaping health disparities.

Feb
11
2019

Biostatistics Seminar

SHOW DETAILS

When: Monday, February 11, 2019
2:00 PM - 3:00 PM CT

Where: 680 N. Lake Shore Drive, Stamer Conference room, Ste 1400, Chicago, IL 60611 map it

Contact: Putri Kusumo   (312) 908-1718

Group: Department of Preventive Medicine

Category: Academic

Description:

 

Presentatation with a Candidate of the Division of Biostatistics / BCC Faculty Position


Hayley Belli, PhD

Postdoctoral Fellow
Division of Biostatistics
New York University Langone School of Medicine

 

Presentation Title:
Improving Patient Outcomes: Adaptive Stage Duration in a Sequential Multiple Assignment Randomized Trial (SMART)



Brief Abstract:
In the era of precision medicine, there is a clear need to design more patient-focused, pragmatic clinical trials. In this talk, I will introduce a statistical method for selecting individualized treatment duration in a Sequential Multiple Assignment Randomized Trial (SMART). In this type of adaptive design, patients move through a series of stages with the option to continue or switch interventions at the end of each stage based on treatment response. Over time, patients will be assigned to more effective interventions. However, under the standard SMART framework, the length of the treatment period is usually fixed, selected by investigators in advance (without much guiding data), and applied uniformly to all participants in the study. We address these shortcomings of SMARTs by introducing a likelihood-based method to determine when an individual patient should stay on a treatment or switch interventions prior to the stage end. This new methodology uses data and design principles to provide patients with treatment options that are advantageous both clinically and ethically, all within the rigorous, experimental framework of a randomized controlled trial. Following derivation, we illustrate the performance of this algorithm using data from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) Study, a two-stage SMART design measuring the effectiveness of sertraline in patients with Major Depressive Disorder.

Feb
15
2019

Cardiovascular Epidemiology Seminar Series

SHOW DETAILS

When: Friday, February 15, 2019
11:00 AM - 12:00 PM CT

Where: 680 N. Lake Shore Drive, Stamer Conference room, Ste 1400, Chicago, IL 60611 map it

Contact: Putri Kusumo   (312) 908-1718

Group: Department of Preventive Medicine

Category: Academic

Description:

 

 

John T. Wilkins, MD, MS, FAHA

Assistant Professor of Cardiology and Preventive Medicine
Department of Preventive Medicine
Feinberg School of Medicine

 


Presentation Title:
Apolipoprotein A-I Proteoforms and Their Associations with HDL Function

 

Objectives:
We will discuss a novel and rapidly developing technology that allows for the characterization and quantification of structural variation (allelic variation and post-translational modification) of ​proteins present in biological samples. We will discuss the implications for the characterization of post-translational modifications to "-omics" and clinical research. Lastly, we will discuss some preliminary results from the CARDIA study that demonstrate associations between specific apolipoprotein A-I structural variants and HDL function. These data provide "proof of concept" that detailed characterization of protein structure may aid in the discovery of novel pathways that mediate cardiovascular health and disease.